NNMT silencing activates tumor suppressor PP2A, inactivates oncogenic STKs, and inhibits tumor forming ability

Clinical Cancer Research

Volumn 23, Issue 9, 2017, Pages 2325-2334

  Palanichamy, Kamalakannan ^a   Kanji, Suman ^a   Gordon, Nicolaus ^a   Thirumoorthy, Krishnan ^a   Jacob, John R ^a   Litzenberg, Kevin T ^a   Patel, DIsha ^a   Chakravarti, Arnab ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINAMIDE; NICOTINAMIDE METHYLTRANSFERASE; PERPHENAZINE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN SERINE THREONINE KINASE; CARBOXYLESTERASE; LEUCINE CARBOXYL METHYLTRANSFERASE-1, HUMAN; NNMT PROTEIN, HUMAN; PROTEIN METHYLTRANSFERASE; PROTEIN PHOSPHATASE METHYLESTERASE-1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PROGNOSIS; CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME INHIBITION; GENE ACTIVATION; GENE INACTIVATION; GENE SILENCING; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE; PROTEIN EXPRESSION; PROTEIN METHYLATION; RADIOSENSITIVITY; TUMOR SUPPRESSOR GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; METHYLATION; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CARBOXYLIC ESTER HYDROLASES; CELL LINE, TUMOR; CELL PROLIFERATION; GENE SILENCING; GENES, TUMOR SUPPRESSOR; GLIOBLASTOMA; HUMANS; METHYLATION; MICE; NICOTINAMIDE N-METHYLTRANSFERASE; PERPHENAZINE; PROTEIN O-METHYLTRANSFERASE; PROTEIN-SERINE-THREONINE KINASES;

EID: 85018412601     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-1323     Document Type: Article

References (50)

1. Wellen KE, Thompson CB. A two-way street: reciprocal regulation of metabolism and signalling. Nat Rev Mol Cell Biol 2012;13:270-6.
2. Lu SC.S-Adenosylmethionine. Int J Biochem Cell Biol 2000;32:391-5.
3. Ulrey CL, Liu L, Andrews LG, Tollefsbol TO. The impact of metabolism on DNA methylation. Hum Mol Genet 2005;14 Spec No1:R139-47.
4. Luo M.Current chemical biology approaches to interrogate protein methyltransferases. ACS Chem Biol 2012;7:443-63.
5. Aksoy S, Szumlanski CL, Weinshilboum RM. Human liver nicotinamide Nmethyltransferase. cDNA cloning, expression, and biochemical characterization. J Biol Chem 1994;269:14835-40.
6. Riederer M, Erwa W, Zimmermann R, Frank S, Zechner R. Adipose tissue as a source of nicotinamide N-methyltransferase and homocysteine. Atherosclerosis 2009;204:412-7.
7. Houtkooper RH, Canto C, Wanders RJ, Auwerx J. The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev 2010;31:194-223.
8. Xu J, Moatamed F, Caldwell JS,Walker JR, Kraiem Z, Taki K, et al. Enhanced expression of nicotinamide N-methyltransferase in human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 2003;88:4990-6.
9. Sartini D, Muzzonigro G, Milanese G, Pierella F, Rossi V, Emanuelli M. Identification of nicotinamide N-methyltransferase as a novel tumor marker for renal clear cell carcinoma. J Urol 2006;176:2248-54.
10. Roessler M, Rollinger W, Palme S, HagmannML, Berndt P, Engel AM, et al. Identification of nicotinamideN-methyltransferase as a novel serum tumor marker for colorectal cancer. Clin Cancer Res 2005;11:6550-7.
11. TomidaM,Mikami I, Takeuchi S,NishimuraH, AkiyamaH. Serum levels of nicotinamide N-methyltransferase in patients with lung cancer. J Cancer Res Clin Oncol 2009;135:1223-9.
12. Emanuelli M, Santarelli A, Sartini D, Ciavarella D, Rossi V, Pozzi V, et al. Nicotinamide N-Methyltransferase upregulation correlates with tumour differentiation in oral squamous cell carcinoma. Histol Histopathol 2010; 25:15-20.
13. Lim BH, Cho BI, Kim YN, Kim JW, Park ST, Lee CW. Overexpression of nicotinamideN-methyltransferase in gastric cancer tissues and its potential post-translational modification. Exp Mol Med 2006;38:455-65.
14. Kim J, Hong SJ, Lim EK, Yu YS, Kim SW, Roh JH, et al. Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis. J Exp Clin Cancer Res 2009;28:20.
15. Zhou W, Gui M, Zhu M, Long Z, Huang L, Zhou J, et al. Nicotinamide-methyltransferase is overexpressed in prostate cancer and correlates with prolonged progression-free and overall survival times. Oncol Lett 2014;8: 1175-80.
16. Sartini D, Muzzonigro G, Milanese G, Pozzi V, Vici A, Morganti S, et al. Upregulation of tissue and urinary nicotinamide N-methyltransferase in bladder cancer: potential for the development of a urine-based diagnostic test. Cell Biochem Biophys 2013;65:473-83.
17. Kassem H, Sangar V, Cowan R, Clarke N, Margison GP. A potential role of heat shock proteins and nicotinamide N-methyl transferase in predicting response to radiation in bladder cancer. Int J Cancer 2002;101:454-60.
18. Wu Y, Siadaty MS, Berens ME, Hampton GM, Theodorescu D. Overlapping gene expression profiles of cell migration and tumor invasion in human bladder cancer identify metallothionein 1E and nicotinamide N-methyltransferase as novel regulators of cell migration. Oncogene 2008;27: 6679-89.
19. Tang SW, Yang TC, Lin WC, Chang WH, Wang CC, Lai MK, et al. NicotinamideN-methyltransferase induces cellular invasion through activating matrix metalloproteinase-2 expression in clear cell renal cell carcinoma cells. Carcinogenesis 2011;32:138-45.
20. Ulanovskaya OA, Zuhl AM, Cravatt BF. NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink. Nat Chem Biol 2013;9:300-6.
21. Palanichamy K, Thirumoorthy K, Kanji S, Gordon N, Singh R, Jacob JR, et al. Methionine and Kynurenine Activate Oncogenic Kinases in Glioblastoma, and Methionine Deprivation Compromises Proliferation. Clin Cancer Res 2016;22:3513-23.
22. Palanichamy K, Acus K, Jacob JR, Chakravarti A. Clinically relevant brain tumor model and device development for experimental therapeutics. J Analytical Oncol 2015;4:5-12.
23. Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, et al. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 2008;26:3015-24.
24. Sablina AA, Hector M, Colpaert N, Hahn WC. Identification of PP2A complexes and pathways involved in cell transformation. Cancer Res 2010;70:10474-84.
25. Chen Z, Gibson TB, Robinson F, Silvestro L, Pearson G, Xu B, et al. MAP kinases. Chem Rev 2001;101:2449-76.
26. Ugi S, Imamura T, Ricketts W, Olefsky JM. Protein phosphatase 2A forms a molecular complex with Shc and regulates Shc tyrosine phosphorylation and downstream mitogenic signaling. Mol Cell Biol 2002;22:2375-87.
27. Shi Y.Serine/threonine phosphatases: mechanism through structure. Cell 2009;139:468-84.
28. Virshup DM, Shenolikar S. From promiscuity to precision: protein phosphatases get a makeover. Mol Cell 2009;33:537-45.
29. Bryant JC, Westphal RS, Wadzinski BE. Methylated C-terminal leucine residue of PP2A catalytic subunit is important for binding of regulatory Balpha subunit. Biochem J 1999;339 (Pt 2):241-6.
30. Ogris E, GibsonDM, Pallas DC. Protein phosphatase 2A subunit assembly: the catalytic subunit carboxy terminus is important for binding cellular B subunit but not polyomavirus middle tumor antigen. Oncogene 1997; 15:911-7.
31. Xie H, Clarke S. Protein phosphatase 2A is reversibly modified by methyl esterification at its C-terminal leucine residue in bovine brain. J Biol Chem 1994;269:1981-4.
32. Lee J, Chen Y, Tolstykh T, Stock J. A specific protein carboxyl methylesterase that demethylates phosphoprotein phosphatase 2A in bovine brain. Proc Natl Acad Sci U S A 1996;93:6043-7.
33. Cantoni GL.The role of S-adenosylhomocysteine in the biological utilization of S-adenosylmethionine. Prog Clin Biol Res 1985;198:47-65.
34. D'Andrea FP, Safwat A, Kassem M, Gautier L, Overgaard J, Horsman MR. Cancer stem cell overexpression of nicotinamide N-methyltransferase enhances cellular radiation resistance. Radiother Oncol 2011; 99:373-8.
35. Pozzi V, Sartini D, Morganti S, Giuliante R, Di Ruscio G, Santarelli A, et al. RNA-mediated gene silencing of nicotinamide N-methyltransferase is associated with decreased tumorigenicity in human oral carcinoma cells. PLoS One 2013;8:e71272.
36. Sartini D, Seta R, Pozzi V, Morganti S, Rubini C, Zizzi A, et al. Role of nicotinamide N-methyltransferase in non-small cell lung cancer: in vitro effect of shRNA-mediated gene silencing on tumourigenicity. Biol Chem 2015;396:225-34.
37. Horsman MR, Siemann DW, Chaplin DJ, Overgaard J. Nicotinamide as a radiosensitizer in tumours and normal tissues: the importance of drug dose and timing. Radiother Oncol 1997;45:167-74.
38. Dominguez-Gomez G, Diaz-Chavez J, Chavez-Blanco A, Gonzalez-Fierro A, Jimenez-Salazar JE,Damian-Matsumura P, et al. Nicotinamide sensitizes human breast cancer cells to the cytotoxic effects of radiation and cisplatin. Oncol Rep 2015;33:721-8.
39. Hoskin PJ, Rojas AM, Saunders MI, Bentzen SM, Motohashi KJ, investigators B. Carbogen and nicotinamide in locally advanced bladder cancer: early results of a phase-III randomized trial. Radiother Oncol 2009;91: 120-5.
40. Chen AC, Martin AJ, Choy B, Fernandez-Penas P, Dalziell RA, McKenzie CA, et al. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med 2015;373:1618-26.
41. Sauve AA.NAD+ and vitamin B3: from metabolism to therapies. J Pharmacol Exp Ther 2008;324:883-93.
42. Sperber H, Mathieu J, Wang Y, Ferreccio A, Hesson J, Xu Z, et al. The metabolome regulates the epigenetic landscape during naive-toprimed human embryonic stem cell transition. Nat Cell Biol 2015; 17:1523-35.
43. De Baere I, Derua R, Janssens V, Van Hoof C, Waelkens E, Merlevede W, et al. Purification of porcine brain protein phosphatase 2A leucine carboxyl methyltransferase and cloning of the human homologue. Biochemistry 1999;38:16539-47.
44. Westermarck J, Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med 2008;14:152-60.
45. Mumby M. PP2A: unveiling a reluctant tumor suppressor. Cell 2007;130: 21-4.
46. Chen W, Arroyo JD, Timmons JC, Possemato R, Hahn WC. Cancerassociated PP2A Aalpha subunits induce functional haploinsufficiency and tumorigenicity. Cancer Res 2005;65:8183-92.
47. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T, et al. CIP2A inhibits PP2A in human malignancies. Cell 2007;130:51-62.
48. Sablina AA, Chen W, Arroyo JD, Corral L, Hector M, Bulmer SE, et al. The tumor suppressor PP2A Abeta regulates the RalA GTPase. Cell 2007; 129:969-82.
49. Sontag JM, Nunbhakdi-Craig V, Mitterhuber M, Ogris E, Sontag E. Regulation of protein phosphatase 2A methylation by LCMT1 and PME-1 plays a critical role in differentiation of neuroblastoma cells. J Neurochem 2010;115:1455-65.
50. Puustinen P, Junttila MR, Vanhatupa S, Sablina AA, Hector ME, Teittinen K, et al. PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma. Cancer Res 2009;69:2870-7.